Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sumatriptan - GlaxoSmithKline

Drug Profile

Sumatriptan - GlaxoSmithKline

Alternative Names: Imigran Nasal Spray; Imitrex Nasal Spray

Latest Information Update: 24 Feb 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Antimigraines; Indoles; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine
  • No development reported Menstrual migraine

Most Recent Events

  • 22 Feb 2016 First Generic equivalent complex product Imitrex® nasal spray approved in USA for Migrane
  • 04 Oct 2013 Launched for Migraine in Argentina, Canada, Indonesia and Israel before 4 October 2013 under the trade name Imitrex® (Intranasal)
  • 02 Feb 2006 Registered for Migraine in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top